CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
We have now added a new section called the "Assay History List" to the "At A Gla...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...